American University of Beirut, Faculty of Health Sciences, Medical Laboratory Sciences Program, 11-0236 Riad El Solh, 1107-2020 Beirut, Lebanon.
University of Pittsburgh, School of Medicine, Department of Microbiology and Molecular Genetics, Pittsburgh, PA 15213, USA.
Virology. 2014 Feb;450-451:34-48. doi: 10.1016/j.virol.2013.10.015. Epub 2013 Dec 20.
It is unclear if HIV-1 variants lose the ability to prime naïve CD8(+) cytotoxic T lymphocytes (CTL) during progressive, untreated infection. We conducted a comprehensive longitudinal analysis of viral evolution and its impact on primary and memory CD8(+) T cell responses pre-seroconversion (SC), post-SC, and during combination antiretroviral therapy (cART). Memory T cell responses targeting autologous virus variants reached a nadir by 8 years post-SC with development of AIDS, followed by a transient enhancement of anti-HIV-1 CTL responses upon initiation of cART. We show broad and high magnitude primary T cell responses to late variants in pre-SC T cells, comparable to primary anti-HIV-1 responses induced in T cells from uninfected persons. Despite evolutionary changes, CD8(+) T cells could still be primed to HIV-1 variants. Hence, vaccination against late, mutated epitopes could be successful in enhancing primary reactivity of T cells for control of the residual reservoir of HIV-1 during cART.
在未经治疗的进展性感染中,HIV-1 变异体是否丧失了对初始 CD8(+)细胞毒性 T 淋巴细胞 (CTL) 的激活能力尚不清楚。我们对病毒进化及其对原发性和记忆性 CD8(+)T 细胞反应的影响进行了全面的纵向分析,这些反应发生在血清转换 (SC) 前、SC 后以及联合抗逆转录病毒治疗 (cART) 期间。针对自体病毒变异体的记忆 T 细胞反应在血清转换后 8 年内达到最低点,随后在开始 cART 时 HIV-1 CTL 反应短暂增强。我们发现,在 SC 前 T 细胞中,针对晚期变异体的广泛且高幅度的原发性 T 细胞反应与未感染者 T 细胞中诱导的原发性抗 HIV-1 反应相当。尽管发生了进化变化,但 CD8(+)T 细胞仍可被 HIV-1 变异体激活。因此,针对晚期突变表位的疫苗接种可能成功增强 T 细胞的原发性反应,从而在 cART 期间控制 HIV-1 的残留库。